Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists

Thrombosis and Haemostasis

Volumn 84, Issue 6, 2000, Pages 1095-1102

  Jennings, L K ^a   Haga, J H ^a   Slack, S M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Antagonists; ELISA; GPIIb IIIa; LIBS; Platelets

Indexed keywords

ABCIXIMAB; EPITOPE; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRONECTIN; MONOCLONAL ANTIBODY; PEPTIDE; TIROFIBAN; TRIPEPTIDE; VITRONECTIN; VON WILLEBRAND FACTOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; THROMBOCYTE;

EID: 0034530276     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614176     Document Type: Article

References (43)

1. The hemostatic plug
2. The role of platelet membrane glycoproteins Ib and IIb-IIIa in platelet adherence to human artery subendothelium
3. Platelet adhesion to extracellular matrices of cultured cells
4. GPIIb-IIIa: The responsive integrin
5. Arg-Gly-Asp: A versatile cell recognition signal
6. New perspectives in cell adhesion: RGD and integrins
7. Evidence that three adhesive proteins interact with a common recognition site on activated platelets
8. Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the gamma chain
9. Evidence that the arginyl-glycyl-aspartate peptides and fibrinogen γ chain peptides share a common binding site on platelets
10. Competition for related but nonidentical binding sites on the glycoprotein IIb-IIIa complex by peptides derived from platelet adhesive proteins
11. Chemical cross-linking of arginyl-glycyl-aspartic acid peptides to an adhesion receptor on platelets
12. Characterization of adhesion of "resting" and stimulated platelets to fibrinogen and its fragments
13. 3
14. von Willebrand factor
15. Exposure of platelet fibrinogen receptors by ADP and epinephrine
16. Interaction of fibrinogen with its platelet receptor as part of a multi-step reaction in ADP-induced platelet aggregation
17. Platelet-collagen adhesion: Inhibition by a monoclonal antibody that binds glycoprotein IIb
18. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers
19. Monoclonal antibodies to ligand-occupied conformers of integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function
20. A conformation-dependent epitope of human platelet glycoprotein IIIa
21. Activation-independent exposure of the GPIIb-IIIa fibrinogen receptor
22. 2+-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a single site on purified platelet glycoprotein IIb-IIIa complex
23. Synthetic peptides derived from fibrinogen and fibronectin change the conformation of purified platelet GPIIb-IIIa
24. Conformational modulation of purified glycoprotein (GP) IIb-IIIa allows proteolytic generation of active fragments from either active or inactive GP IIb-IIIa
25. 3 (GPIIb-IIIa) assumes an active, ligand-binding conformation and is recognized by GPIIb-IIIa-specific monoclonal, allo-, auto-, and drug-dependent platelet antibodies
26. Blockade of platelet GPIIb/IIIa as an antithrombotic strategy
27. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
28. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
29. Eptifibatide
30. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation
31. ffects of competitive platelet glycoprotein IIb/IIIa inhibition with integrelin in reducing complications of percutaneous coronary intervention
32. Tirofiban
33. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina
34. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
35. Potential non-glycoprotein IIb/IIIa effects of abciximab
36. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM
37. 3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function
38. A method for purifying the platelet membrane glycoprotein IIb-IIIa complex
39. Biostatistics
40. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa
41. Inhibition of fibrinogen binding and surface recruitment of GPIIb/IIIa as dose-dependent effects of the RGD-mimetic MK-852
42. 3 inhibitors
43. Selective induction of a GPIIIa LIBS by fibrinogen and von Willebrand Factor